195 related articles for article (PubMed ID: 35699112)
1. Meta-analysis of cardiovascular outcome trials assessing the impact of glucagon-like peptide-1 receptor agonists on major cardiac arrhythmias.
Boulmpou A; Patoulias D; Papadopoulos CE; Teperikidis E; Doumas M; Vassilikos V
Acta Cardiol; 2023 Jul; 78(5):519-524. PubMed ID: 35699112
[TBL] [Abstract][Full Text] [Related]
2. Effects of GLP-1 receptor agonists on arrhythmias and its subtypes in patients with type 2 diabetes: A systematic review and meta-analysis.
Wei J; Wang R; Ye H; Wang Y; Wang L; Zhang X
Front Endocrinol (Lausanne); 2022; 13():910256. PubMed ID: 36034440
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide Receptor Agonists for Atrial Fibrillation in Type 2 Diabetes Mellitus: Systematic Review With Network Meta-analysis of Randomized Controlled Trials.
Li W; Chen X; Xie X; Xu M; Xu L; Liu P; Luo B
J Cardiovasc Pharmacol; 2022 Mar; 79(3):281-288. PubMed ID: 34935705
[TBL] [Abstract][Full Text] [Related]
4. A meta-analysis evaluating indirectly GLP-1 receptor agonists and arrhythmias in patients with type 2 diabetes and myocardial infarction.
Liu Z; Bian N; Wu S; Fan Y; Li H; Yu J; Guo J; Chen D
Front Cardiovasc Med; 2022; 9():1019120. PubMed ID: 36277800
[TBL] [Abstract][Full Text] [Related]
5. Effect of Glucagon-like Peptide-1 Receptor Agonists on Prognosis of Heart Failure and Cardiac Function: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Huixing L; Di F; Daoquan P
Clin Ther; 2023 Jan; 45(1):17-30. PubMed ID: 36604209
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy of sodium-glucose co-transporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: A systematic review and network meta-analysis.
Nguyen BN; Nguyen L; Mital S; Bugden S; Nguyen HV
Diabetes Obes Metab; 2023 Jun; 25(6):1614-1623. PubMed ID: 36751968
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of drugs for people with type 2 diabetes mellitus and chronic kidney disease on kidney and cardiovascular outcomes: A systematic review and network meta-analysis of randomized controlled trials.
Yang Q; Lang Y; Yang W; Yang F; Yang J; Wu Y; Xiao X; Qin C; Zou Y; Zhao Y; Kang D; Liu F
Diabetes Res Clin Pract; 2023 Apr; 198():110592. PubMed ID: 36842477
[TBL] [Abstract][Full Text] [Related]
8. GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Banerjee M; Pal R; Mukhopadhyay S; Nair K
J Clin Endocrinol Metab; 2023 Jun; 108(7):1806-1812. PubMed ID: 36800286
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
Zhu Y; Xu J; Zhang D; Mu X; Shi Y; Chen S; Wu Z; Li S
Front Endocrinol (Lausanne); 2021; 12():769069. PubMed ID: 34956080
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide-1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: An updated meta-analysis and subgroup analysis of randomized controlled trials.
Mannucci E; Dicembrini I; Nreu B; Monami M
Diabetes Obes Metab; 2020 Feb; 22(2):203-211. PubMed ID: 31595657
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis.
Hussein H; Zaccardi F; Khunti K; Seidu S; Davies MJ; Gray LJ
Diabet Med; 2019 Apr; 36(4):444-452. PubMed ID: 30653708
[TBL] [Abstract][Full Text] [Related]
12. Effects of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) on Cardiac Structure and Function: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials.
Wong SY; Lee ARYB; Sia AHJ; Wo YJ; Teo YH; Teo YN; Syn NL; Ong CC; Teo LL; Yeo TC; Poh KK; Kong WK; Wong RC; Sia CH
Cardiovasc Drugs Ther; 2024 Apr; 38(2):371-389. PubMed ID: 35819544
[TBL] [Abstract][Full Text] [Related]
13. Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials.
Qin J; Song L
BMC Endocr Disord; 2022 May; 22(1):125. PubMed ID: 35546664
[TBL] [Abstract][Full Text] [Related]
14. Impact of a dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta-analysis.
Yang Y; He L; Liu P; Wang J; Yang N; Li Z; Ping F; Xu L; Li W; Zhang H; Li Y
Diabetes Obes Metab; 2024 Feb; 26(2):548-556. PubMed ID: 37860884
[TBL] [Abstract][Full Text] [Related]
15. Sodium glucose cotransporter 2 inhibitors with cardiac arrhythmias in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized placebo-controlled trials.
Xu B; Kang B; Zhou J
Clin Res Cardiol; 2024 Jun; 113(6):910-923. PubMed ID: 38353684
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
Pinelli NR; Hurren KM
Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
[TBL] [Abstract][Full Text] [Related]
17. The effect of glucagon-like peptide-1 receptor agonists on cardiac function and structure in patients with or without type 2 diabetes mellitus: An updated systematic review and meta-analysis.
Zhang Y; Yang D; Jia Q; Yan J; An F
Diabetes Obes Metab; 2024 Jun; 26(6):2401-2411. PubMed ID: 38528818
[TBL] [Abstract][Full Text] [Related]
18. Association of glucagon-like peptide-1 receptor agonists with cardiac arrhythmias in patients with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized controlled trials.
Wu S; Lu W; Chen Z; Dai Y; Chen K; Zhang S
Diabetol Metab Syndr; 2022 Dec; 14(1):195. PubMed ID: 36572913
[TBL] [Abstract][Full Text] [Related]
19. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.
Ji Q
Clin Ther; 2017 Jun; 39(6):1244-1264. PubMed ID: 28526416
[TBL] [Abstract][Full Text] [Related]
20. Tumour Risk with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus Patients: A Systematic Review.
Guo X; Yang Q; Dong J; Liao L; Zhang W; Liu F
Clin Drug Investig; 2016 Jun; 36(6):433-41. PubMed ID: 26979594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]